Democritus University of Thrace (DUTH)
The role of aldehyde dehydrogenases (ALDHs) in cancer stem cells
Abstract
dc:descriptionAldehyde dehydrogenases (ALDHs) are NAD(P)+-dependent enzymes that catalyze the oxidation of endogenous (lipids, amino acids and vitamins) and exogenous (ethanol and drugs) aldehydes to their corresponding carboxylic acids. ALDHs have been used as normal and cancer stem cell (CSC) markers in a wide spectrum of solid tumors and hematological malignancies, are related to increased tumorgenicity, chemo/radio-resistance, cancer initiation and progression and participate in a variety of cellular mechanisms, such as metabolism, proliferation, differentiation, embryogenesis, apoptosis, stemness, invasion, hypoxia, as well as in RA biosynthesis.ALDH1B1, a member of ALDHs superfamily, is a mitochondrial enzyme that detoxifies 4-HNE and malondialdehyde and may be associated with RA metabolism. It is suggested that ALDH1B1 is associated with ethanol metabolism and maintenance of stallion sperm motility. It is also correlated with colon tumorigenesis, pancreatic stem cells and beta cell development and involved in various cellular signaling pathways such as PI3K/Akt, Wnt/β-catenin and Notch, demonstrating thus its potential relation to CSC phenotype. Moreover, studies have reported that ALDH1B1 could be a novel biomarker for detecting colorectal cancer and may be a modulator of pancreatic cancer.CSCs, also known as tumor initiating cells, are characterized by a set of stem-like properties, such as self-renewal, differentiation, cell survival and asymmetric cell division. CSCs are considered important for tumor heterogeneity due to their ability to differentiate into multiple cell types, while they are considered important therapeutic target as a result of their enhanced chemo- and radio-resistance as well as their association with cancer initiation, progression and metastasis.Silibinin is the major bioactive and most abundant component of the silymarin complex derived from the seeds of the plant Silybum marianum. Silibinin consists of a diastereoisomeric mixture of silybin A and silybin B and is reported as a compound with a safe profile, due to its low cytotoxicity against healthy cells. Plenty of studies have supported the strong chemopreventive and antineoplastic ability of silibinin through pleiotropic mechanisms of action against different type of malignancies. The present study examines the role of ALDHs in CSCs. It focuses on the pathophysiological role of ALDH1B1 in colorectal and lung carcinoma demonstrating the molecular mechanisms, in which ALDH1B1 is involved. In addition, we investigated which ALDH isoforms are associated with sphere phenotype and the potential effect of silibinin in inhibiting the sphere formation efficiency. For examining the pathophysiological role of ALDH1B1, we established two isogenic cell line pairs for human colorectal adenocarcinoma (HT-29 and Caco-2) and one isogenic cell line pair for lung carcinoma (A549), differing only in the expression of ALDH1B1. ALDH1B1 appears to be implicated in cell cycle regulation as the ALDH1B1-overexpressing cells exhibited significantly slower growth rates and a G2/M phase cell cycle arrest compared to the HT-29/mock cells. Furthermore, ALDH1B1 expression was related to enhanced chemoresistance as it protects HT-29 and A549 cells from cytotoxic effects of different chemotherapeutic agents (etoposide, DOX, 5-FU). Moreover, ALDH1B1 was correlated with EMT induction through ZEB1 or SNAIL signaling pathways and morphological alterations (HT-29, Caco-2 and A549) and exhibited increased migratory potential in HT-29 cells. ALDH1B1 expression was accompanied by increased constitutive phosphorylation of p53 and H2AX at basal levels, in HT-29/ALDH1B1 compared to HT-29/mock cells, protecting cells from the genotoxic effect of etoposide. Interestingly, real-time PCR revealed that the expression of ALDH1B1 significantly altered the expression profile of a variety of DNA damage response-related genes between the isogenic ΗΤ-29 cell lines. In particular, four important genes of DNA damage repair (MRE11A, PMS1, RAD18, and UNG) were found to be up-regulated in the ALDH1B1-overexpressing HT-29 cells at basal levels.Additionally, we utilized lung (A549) and hepatocellular (HepG2) cancer cells and generated tumor spheres to isolate the CSC sub-population. The CSC enrichment was confirmed by the up-regulation of CSC-related genes, such as EpCAM, OCT4, SOX2, SOX4, CXCR4, CD49f and NOTCH1. Real-time PCR analysis indicated the up-regulation of several ALDH isoforms such as ALDH1A1, ALDH2, ALDH3A1, ALDH3B1 in A549 and ALDH1A3, ALDH3A1, ALDH9A1 and ALDH18A1 in HepG2 spheres. Interestingly, cyclin D1 and Akt, down-stream targets of the RA signaling pathway, were also shown to be significantly up-regulated in both sphere populations. Specific ALDH isoforms appear to be important mediators for the acquisition of CSC phenotype and maybe promising targets for CSC-based therapeutic approaches in lung and hepatocellular carcinomas.Finally, we assessed the silibinin potential effect on sphere cultures of A549 and HepG2. We determined its cytotoxicity profile in A549 cells and then we evaluated its anti-proliferative effect in both A549 and HepG2 cells. Then, we found that silibinin induced the mRNA down-regulation of specific sphere-related ALDH isoforms and CSC markers as well as it triggered substantial decrease in the ALDH enzymatic activity. Silibinin inhibited the sphere formation efficacy of A549 and HepG2 cells, indicating that it could be considered a potential agent for the CSC-based therapeutic approach.In conclusion, the results of the present study underline the potential significance of ALDH1B1 in cancer progression as it was found that ALDH1B1 confers alterations in the cell morphology, cell cycle progression and gene expression, accompanied by significant changes in the chemosensitivity and migratory potential of colon and lung cancer cells, features related to the acquisition of a CSC phenotype. The results of this study, also, demonstrate that other ALDH isoforms may be associated with the CSC phenotype using preclinical lung and hepatocellular cancer models. Further studies are required to clarify the exact role of ALDHs in cancer stem cell biology and to enable future studies for CSC-based therapies.
Degree
thesis:*- Grantor dc:publisher
- Democritus University of Thrace (DUTH)
- Year dc:date
- 2021
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Tsochantaridis, Ilias
- Τσοχανταρίδης, Ηλίας
Subjects
dc:subject × 24- Αλδεϋδικές αφυδρογονάσες (ALDHs)
- Καρκινικά βλαστικά κύτταρα
- Αλδεϋδική αφυδρογονάση 1B1 (ALDH1B1)
- Αλδεϋδική αφυδρογονάση 3A1 (ALDH3A1)
- Καρκίνος του παχέος εντέρου (CRC)
- Καρκίνος του πνεύμονα
- Aldehyde dehydrogenases (ALDHs)
- Cancer stem cells
- Aldehyde dehydrogenase 1B1 (ALDH1B1)
- Aldehyde dehydrogenase 3A1 (ALDH3A1)
- Colorectal adenocarcinoma
- Lung adenocarcinoma
- Βιολογία
- Φυσικές Επιστήμες
- Βιοχημεία και Μοριακή βιολογία
- Βασική Ιατρική
- Ιατρική και Επιστήμες Υγείας
- Φυσιολογία
- Biological Sciences
- Natural Sciences
- Biochemistry and Molecular Biology
- Basic Medicine
- Medical and Health Sciences
- Physiology
Rights
- Language dc:language
- eng
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/50669